Palbociclib Hydrochloride (20:37) and its Impurities
Palbociclib Hydrochloride (20:37), sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. Reference standards of Palbociclib Hydrochloride (20:37) API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

 
	
			                                   
																				 
 
 
 
